Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 10, 2013
Langzeitdaten in The Journal of Allergy and Clinical Immunology veröffentlicht: Patienten mit schwerem Asthma profitieren für Jahre von einer nicht-medikamentösen Therapie, wo Medikamente...
-
Sep 9, 2013I benefici comportati dalla termoplastica bronchiale perdurano per anni, anziché per ore, diversamente da quanto accade col solo trattamento farmacologico.
News Newsroom Italia Asma grave Archivio Comunicati Stampa 2013 Sep 09, 2013 Comunicato Stampa The Journal of Allergy and Clinical Immunology pubblica i dati sulla termoplastica bronchiale che...
-
Sep 4, 2013Unlike Medications Alone, Bronchial Thermoplasty Provides Benefits That Last for Years Rather Than Hours
A breakthrough Boston Scientific technology for the treatment of severe asthma has been shown to be safe and effective over at least five years, according to data published online in a key medical...
-
Jul 19, 2013
First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System Boston Scientific Corporation (NYSE: BSX) has launched a...
-
Jul 19, 2013
First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System Boston Scientific Corporation (NYSE: BSX) has launched a...
-
Jul 19, 2013Boston Scientific Launches Trial To Evaluate Neurostimulation For Treatment Of Chronic Migraine [EN]First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System
Boston Scientific Corporation (NYSE: BSX) has launched a clinical trial to determine whether occipital nerve stimulation (ONS) using the Precision™ System can safely and effectively treat...
-
Jun 28, 2013Transaction to Accelerate Boston Scientific Expansion in Growing Electrophysiology Market
In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific Corporation (NYSE:BSX) has entered into a...
-
Jun 26, 2013
The first patient implant of the Boston Scientific Corporation (NYSE: BSX) VITALIO™ pacemaker was performed at ZGT Hengelo in Hengelo, the Netherlands. In addition to a comprehensive suite of...
-
Jun 25, 2013
Boston Scientific Corporation (NYSE: BSX) is launching a new family of pacemakers in Europe. These pacemakers monitor respiration, adjust pacing accordingly, and support insight into the patient?s...
-
Jun 24, 2013Outcomes Follow Recent NICE Guidance Supporting Safety and Effectiveness of Subcutaneous Implantable Defibrillators
The Boston Scientific Corporation (NYSE:BSX) S-ICD® (subcutaneous implantable defibrillator) System showed a significant reduction in major lead-related complications when compared with both...
-
May 28, 2013
Boston Scientific Corporation (NYSE: BSX) presenta i risultati positivi di due studi clinici riguardanti nuove ed innovative tecnologie di stent medicati (DES), che rappresentano opzioni...
-
May 28, 2013Nuovi dati clinici sono stati presentati durante l'EuroPCR nel corso di una Late Breaking Clinical Trial Session e hanno dimostrato risultati positivi in termini di minino rigurgito paravalvolare, a 30 giorni, nei primi 60 pazienti trattati con la valvola Lotus™
Boston Scientific Corporation (NYSE: BSX) presenta i risultati positivi di un'analisi pre-specificata dei primi 60 pazienti arruolati nello studio REPRISE II, che valuta la performance e la...
-
May 27, 2013In einer Late-Breaking-Session des EuroPCR Kongresses wurden neue Daten zum erfolgreichen Einsatz derLotus™-Aortenklappe für die ersten 60 Patienten der REPRISE II Studie vorgestellt. Nach 30 Tagen traten kaum Fälle einer paravalvulären Aorteninsuffizienz auf.
Die Boston Scientific Corporation (NYSE: Adaptive Seal™" zur Minimierung paravalvulärer Lecks. Letztere sind ein Mortalitätsprädiktor. Die Klappe ist repositionierbar und bergbar (vor dem...
-
May 27, 2013
Die Boston Scientific Corporation (NYSE: BSX) hat positive Ergebnisse zweier Studien zur innovativen Technologie medikamentenfreisetzender Stents (DES), die sich als richtungsweisende Behandlungen...
-
May 27, 2013Presentados hoy en EuroPCR los datos provisionales del programa clínico REDUCE-HTN
Boston Scientific Corporation (NYSE: BSX) ha anunciado hoy los datos provisionales del programa clínico REDUCE-HTN, que demuestran una reducción significativa y duradera de la tensión arterial...
-
May 27, 2013Interimdaten aus dem klinischen Programm REDUCE-HTN wurden heute auf dem EuroPCR präsentiert
Boston Scientific Corporation (NYSE: BSX) hat heute Interimdaten aus dem klinischen Programm REDUCE-HTN präsentiert, die eine signifikante und nachhaltige Reduktion des Blutdrucks bei Patienten...
-
May 22, 2013
Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for...
-
May 22, 2013
Boston Scientific Corporation (NYSE: BSX) reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II trial evaluating the performance and safety of...
-
May 22, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX) Alair® Bronchial Thermoplasty (BT)...
-
May 21, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX) Alair® Bronchial Thermoplasty (BT)...
-
May 21, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX) Alair® Bronchial Thermoplasty (BT)...
-
May 21, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX) Alair® Bronchial Thermoplasty (BT)...
-
May 17, 2013
"We are pleased to present a particularly rich and diversified set of data this year at EuroPCR," said Keith Dawkins, M.D., global chief medical officer, Boston Scientific. "The primary endpoint...
-
May 17, 2013
Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris. "We are pleased to present a particularly rich and diversified set...
-
May 17, 2013
Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial Results of REPRISE I Study Suggest Device Minimizes Aortic Regurgitation Boston Scientific Corporation...